[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618239":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":35,"responsibleParty":52,"collaborators":18,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":18,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":18,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Institute for Clinical and Experimental Medicine","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ALSS (alternating DPMAS and TPE)","EXPERIMENTAL","Participants meeting inclusion criteria will receive artificial liver support system (ALSS) therapy in addition to standard of care. ALSS sessions will be performed for up to 7-10 days or until liver transplantation or recovery of hepatic function, whichever occurs first. ALSS modalities will be alternated according to protocol (DPMAS and TPE alternating between sessions). Outcomes will be assessed through Day 28 after hospital admission (or per protocol).",[13],"Device: The artificial liver support system (ALSS) - DPMAS\u002FTPE",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard care","NO_INTERVENTION","Participants will receive standard of care for ACLF according to institutional protocol without ALSS (no DPMAS and no TPE as part of ALSS).",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","The artificial liver support system (ALSS) - DPMAS\u002FTPE","Device: Double Plasma Molecular Adsorption System (DPMAS) Procedure\u002FOther: Therapeutic Plasma Exchange (TPE)",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Petr Piza, MD, MHA","CONTACT","+420 602 225 077","petr.piza@ikem.cz",{"name":32,"role":28,"phone":33,"phoneExt":18,"email":34},"Eva Kieslichova, ass. prof., MD, PhD","+420 261 363 350","evki@ikem.cz",[36],{"facility":37,"status":38,"city":39,"state":18,"zip":40,"country":41,"countryCode":18,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Institute for Clinical and Experimental Medicine (IKEM)","RECRUITING","Prague","14200","Czechia",{"type":43,"coordinates":44},"Point",[45,46],14.42076,50.08804,{"lat":46,"lon":45},[49],{"name":50,"role":28,"phone":51,"phoneExt":18,"email":30},"Petr Piza, MD","+420602225077",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Petr Piza","anesthesiologist\u002Fintensivist","100618239","alss---dpmas-and-therapeutic-plasma-exchange-tpe-its-effect-on-primary-coagulation-inflammation-and-the-function-of-vital-organs-in-alf-or-aclf-100618239",false,"NCT07329036","ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF","The Artificial Liver Support System (ALSS) in Patients With Acute on Chronic Liver Failure - the Use of Combined Molecular Adsorption System With Double Plasma (DPMAS) and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation and the Function of Vital Organs.","Inclusion Criteria:\n\n* Adult patient, age ≥18 years\n* Expressed consent to the inclusion\n* Patient hospitalized on ICU with ALF or ACLF diagnosis\n* Recently meeting the inclusion to liver transplantation\n* Present on a waiting list to liver transplant\n* Unsuitable for inclusion to liver transplantation - indicated for support therapy only, but not indented to palliative care\n\nExclusion Criteria:\n\n* Disagreement with the study\n* Infaust prognosis with expected survival less than 24 hours\n* Physiologically\u002Fbiologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA III or IV) or neurological disease, as well as ACLF-3.\n* Advanced oncological disease (expected life expectancy below 6 months)\n* Severe degree of Frailty syndrome in secondary severe sarcopenia (muscle and malnutrition) or reduced performance state according","ALL","18 Years","75 Years",{"count":67,"type":68},25,"ESTIMATED","INTERVENTIONAL",[71],"NA","The artificial liver support system (ALSS) in patients with acute on chronic liver failure - the use of combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE), its effect on primary coagulation, inflammation and the function of vital organs.",[74],"Acute Liver Failure",[76],"acute liver failure","2025-12-28",{"date":79,"type":80},"2026-01-09","ACTUAL",{"date":82,"type":80},"2024-04-01",{"date":84,"type":68},"2026-12-31",{"name":5,"class":6},1]